Zentalis Pharmaceuticals, Inc. Stock-Based Compensation
Zentalis Pharmaceuticals, Inc. (ZNTL) reported Stock-Based Compensation of $6.41 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-06
- Zentalis Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $3.21M, a 48.85% decline year-over-year.
- Zentalis Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $3.20M, a 50.71% decline year-over-year.
- Zentalis Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $3.12M, a 90.05% decline year-over-year.
- Zentalis Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $4.83M, a 53.41% decline year-over-year.
- Zentalis Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $20.72M, a 69.20% decline from fiscal 2024.
- Zentalis Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $67.27M, a 22.70% increase from fiscal 2023.
- Zentalis Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $54.82M, a 17.04% increase from fiscal 2022.
- Zentalis Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $46.84M, a 31.07% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $6.41M 10-Q · filed 2026-08-06 | $9.53M derived: sum of 3 quarters · filed 2026-08-06 | $14.36M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $3.20M 10-Q · filed 2026-05-12 | $6.32M derived: sum of 2 quarters · filed 2026-05-12 | $11.15M derived: sum of 3 quarters · filed 2026-05-12 | $17.43M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $3.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $7.95M derived: sum of 2 quarters · filed 2026-03-26 | $14.24M derived: sum of 3 quarters · filed 2026-08-06 | $20.72M 10-K · filed 2026-03-26 |
| 2025-09-30 | $4.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $11.11M derived: sum of 2 quarters · filed 2026-08-06 | $17.60M 10-Q · filed 2025-11-10 | $48.96M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $6.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $12.77M 10-Q · filed 2026-08-06 | $44.13M derived: sum of 3 quarters · filed 2026-08-06 | $54.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $6.49M 10-Q · filed 2026-05-12 | $37.85M derived: sum of 2 quarters · filed 2026-05-12 | $48.21M derived: sum of 3 quarters · filed 2026-05-12 | $60.92M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $31.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $41.73M derived: sum of 2 quarters · filed 2026-03-26 | $54.44M derived: sum of 3 quarters · filed 2026-03-26 | $67.27M 10-K · filed 2026-03-26 |
| 2024-09-30 | $10.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $23.07M derived: sum of 2 quarters · filed 2025-11-10 | $35.91M 10-Q · filed 2025-11-10 | $49.79M derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-06-30 | $12.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $25.54M 10-Q · filed 2025-08-06 | $39.42M derived: sum of 3 quarters · filed 2026-03-26 | $53.29M derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-03-31 | $12.83M 10-Q · filed 2025-05-14 | $26.71M derived: sum of 2 quarters · filed 2026-03-26 | $40.58M derived: sum of 3 quarters · filed 2026-03-26 | $53.92M derived: sum of 4 quarters · filed 2026-03-26 |
| 2023-12-31 | $13.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $27.75M derived: sum of 2 quarters · filed 2026-03-26 | $41.09M derived: sum of 3 quarters · filed 2026-03-26 | $54.82M 10-K · filed 2026-03-26 |
| 2023-09-30 | $13.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $27.21M derived: sum of 2 quarters · filed 2024-11-12 | $40.94M 10-Q · filed 2024-11-12 | $50.55M derived: sum of 4 quarters · filed 2025-03-26 |
| 2023-06-30 | $13.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $27.07M 10-Q · filed 2024-08-09 | $36.69M derived: sum of 3 quarters · filed 2025-03-26 | $47.00M derived: sum of 4 quarters · filed 2025-03-26 |
| 2023-03-31 | $13.73M 10-Q · filed 2024-05-07 | $23.34M derived: sum of 2 quarters · filed 2025-03-26 | $33.66M derived: sum of 3 quarters · filed 2025-03-26 | $50.43M derived: sum of 4 quarters · filed 2025-03-26 |
| 2022-12-31 | $9.61M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $19.93M derived: sum of 2 quarters · filed 2025-03-26 | $36.69M derived: sum of 3 quarters · filed 2025-03-26 | $46.84M 10-K · filed 2025-03-26 |
| 2022-09-30 | $10.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $27.08M derived: sum of 2 quarters · filed 2023-11-06 | $37.23M 10-Q · filed 2023-11-06 | $45.70M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $16.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $26.91M 10-Q · filed 2023-08-09 | $35.38M derived: sum of 3 quarters · filed 2024-02-27 | $43.04M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $10.15M 10-Q · filed 2023-05-10 | $18.62M derived: sum of 2 quarters · filed 2024-02-27 | $26.27M derived: sum of 3 quarters · filed 2024-02-27 | $36.19M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $8.47M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $16.13M derived: sum of 2 quarters · filed 2024-02-27 | $26.05M derived: sum of 3 quarters · filed 2024-02-27 | $35.74M 10-K · filed 2024-02-27 |
| 2021-09-30 | $7.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $17.57M derived: sum of 2 quarters · filed 2022-11-09 | $27.27M 10-Q · filed 2022-11-09 | $35.15M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $9.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $19.61M 10-Q · filed 2022-08-09 | $27.50M derived: sum of 3 quarters · filed 2023-03-01 | $34.75M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $9.69M 10-Q · filed 2022-05-05 | $17.58M derived: sum of 2 quarters · filed 2023-03-01 | $24.83M derived: sum of 3 quarters · filed 2023-03-01 | $32.51M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $7.89M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $15.14M derived: sum of 2 quarters · filed 2023-03-01 | $22.82M derived: sum of 3 quarters · filed 2023-03-01 | $23.15M 10-K · filed 2023-03-01 |
| 2020-09-30 | $7.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $14.93M derived: sum of 2 quarters · filed 2021-11-10 | $15.26M 10-Q · filed 2021-11-10 | $15.47M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $7.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $8.01M 10-Q · filed 2021-08-12 | $8.22M derived: sum of 3 quarters · filed 2022-02-24 | $8.38M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $329.00K 10-Q · filed 2021-05-17 | $541.00K derived: sum of 2 quarters · filed 2022-02-24 | $696.00K derived: sum of 3 quarters · filed 2022-02-24 | $817.00K derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $212.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $367.00K derived: sum of 2 quarters · filed 2022-02-24 | $488.00K derived: sum of 3 quarters · filed 2022-02-24 | $617.00K 10-K · filed 2022-02-24 |
| 2019-09-30 | $155.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $276.00K derived: sum of 2 quarters · filed 2020-11-09 | $405.00K 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $121.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | $250.00K 10-Q · filed 2020-08-13 | ||
| 2019-03-31 | $129.00K 10-Q · filed 2020-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |